Brief: Portage Biotech Inc Highlights First Patient Dosed In IMP-MEL Study Of PORT-2
05/08/2021 16:32
Aug 5 (Reuters) - Portage Biotech Inc PRTG.O :
* PORTAGE BIOTECH INC - HIGHLIGHTS FIRST PATIENT DOSED IN
IMP-MEL
STUDY OF PORT-2 FOR TREATMENT OF MELANOMA AND NON-SMALL CELL
LUNG CANCER (NSCLC)
Source text for Eikon: ID:nGNX8DpDCH
Further company coverage: PRTG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data